The Next Fat Pill

Dolan, Kerry A.
October 2007
Forbes Asia;10/29/2007, Vol. 3 Issue 18, p84
The article features a weight-loss drug being developed in the U.S. A third of U.S. adults are obese, an epidemic that tacks on myriad risks, including diabetes and cardiovascular disease. Arena Pharmaceuticals Chief Executive Jack Lief introduces a new weight-loss pill called lorcaserin, which stimulates production of serotonin. In mid-September a firm not affiliated with Arena found no safety problems after monitoring the hearts of people on lorcaserin for 6 months.


Related Articles

  • Chapter 1: Battle of the Bulge. Libal, Autumn // Fitness Factor: The Importance of Physical Activity & Exercise;2005, p9 

    This article discusses the threats posed by the obesity epidemic among U.S. citizens. Two out of every three U.S. adults are overweight and one out of three U.S. adults is officially obese. The crisis is also spreading to young people like never before. One out of every six people between the...

  • Lorcaserin zur Gewichtsreduktion bei übergewichtigen und adipösen Erwachsenen. Spaar, Anne // Praxis (16618157);11/17/2010, Vol. 99 Issue 23, p1437 

    No abstract available.

  • Zonisamide/bupropion combo associated with 15% weight loss in obese individuals.  // Endocrine Today;11/10/2008, Vol. 6 Issue 20, p7 

    The article discusses a study of the effect of a combination of zonisamide and bupropion on obese individuals, presented at the Obesity Society Annual Scientific Meeting in Phoenix, Arizona. Results showed that 56 individuals experienced a mean weight loss of 14% and 37 individuals achieved a...

  • Behind The Headlines: Jab may replace obesity surgery. Baines, Emma // GP: General Practitioner;8/5/2005, p12 

    The article focuses on a hormone injection to help weight loss. A hormone treatment that 'switches off' the appetite could help overweight people to lose more than five pounds a month, according to media reports. The papers claimed that by taking an injection of the hormone oxyntomodulin half an...

  • Metformin.  // Reactions Weekly;11/4/2006, Issue 1126, p15 

    The article presents a case report on metformin treatment of a 33-year-old obese woman. The woman developed leukocytoclastic vasculitis during self-treatment with metformin to lose weight. On examination, she had purpuric exanthema with palpable lesions on her lower extremities. After initiating...

  • Sibutramine: balanced judgment or prejudice? Coutinho, Walmir; James, W. Philip T. // Revista Brasileira de Psiquiatria;jun2011, Vol. 33 Issue 2, p115 

    The author expresses his concern on the way the anti-obesity agent, sibutramine, was evaluated for its potential impact on cardiovascular risk by the Sibutramine Cardiosvascular Outcome Trial (SCOUT). He says that the results should not be applied to the general population of obese patients...

  • Pill Poppers. Litke, Cara // Allure;Mar2008, p40 

    The article focuses on the launch of Alli, the first weight-loss pill for use without a prescription approved by the U.S. Food & Drug Administration. According to the author, the drug works by blocking the absorption of a quarter of the fat in all ingested foods. The fat passes through the body...

  • Daily Reminders Help Dieters Stay On Track.  // Executive Health's Good Health Report;Oct99, Vol. 36 Issue 1, p6 

    Discusses a study which suggested that contact with weight counselors help obese individuals stick to their weight loss program.

  • Non-surgical program, primary care practices helped morbidly obese patients lose weight. Brannon, Matthew // Endocrine Today;Feb2010, Vol. 8 Issue 2, p19 

    The article discusses research on a non-surgical program designed to help morbidly obese people to loose weight, by D. H. Ryan and colleagues, published in the 2010 issue of "Archives of Internal Medicine."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics